0001104659-17-044530.txt : 20170711
0001104659-17-044530.hdr.sgml : 20170711
20170711174032
ACCESSION NUMBER: 0001104659-17-044530
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170707
FILED AS OF DATE: 20170711
DATE AS OF CHANGE: 20170711
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FORMELA JEAN FRANCOIS
CENTRAL INDEX KEY: 0001030575
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 17960631
MAIL ADDRESS:
STREET 1: C/O ATLAS VENTURE
STREET 2: 890 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
a4.xml
4
X0306
4
2017-07-07
0
0001652130
Intellia Therapeutics, Inc.
NTLA
0001030575
FORMELA JEAN FRANCOIS
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET, SUITE 130
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2017-07-07
4
S
0
30000
16.7664
D
3699788
I
See Footnote
Common Stock
2017-07-10
4
S
0
40000
16.1722
D
3659788
I
See Footnote
Common Stock
2017-07-11
4
S
0
80000
16.0695
D
3579788
I
See Footnote
Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 - $17.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 - $16.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 - $16.325, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4.
Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of his pecuniary interest therein, if any.
Exhibit 24 - Power of Attorney (incorporated by reference to Exhibit 24, Power of Attorney, filed on Form 4 with the SEC on March 13, 2017 by the reporting person)
By: /s/ Frank Castellucci, Attorney-In-Fact
2017-07-11